|Experience, Success, And Dedication
To Cancer Treatment
CGT is led by an experienced team of biotechnology researchers and executives with proven track records in the creation, development and successful market introduction of biotechnology therapeutic products.
Denise Harrison, Chief Executive Officer
Denise Harrison, Chief Executive Officer, President, Board Member
Thomas P. Hopp, PhD, Vice President, Research and Development
Prior to joining CG Therapeutics, Tom held a senior position at Corus Pharmaceuticals and was Chief Scientific Officer at ImmunoTherapy Corp. He was an Associate Member of the Torrey Pines Institute for Molecular Studies in San Diego and consulted with Houghten Pharmaceuticals Inc., to help create their product development plan. He also served as Director of Technical Development for Multiple Peptide Systems, establishing large-scale production methods for polypeptide combinatorial libraries. Prior to that, he was President of Protein Research Laboratories, Inc. and Vice President of New Research Evaluation for Immunex Corporation. Tom earned his B.S. in Molecular Biology from the University of Washington and a Ph.D. in Biochemistry from Cornell University Medical College. He completed post-doctoral training with two Nobel laureates at Rockefeller University, studying protein chemistry with Dr. G. M. Edelman and peptide chemistry with Dr. R. B. Merrifield.
Gordon Duncan, PhD, Chief Clinical Officer
Gordon spent 20 years with the Upjohn Company as a Vice President and Executive Director. His duties included major roles in Upjohn’s drug discovery, drug development and clinical development efforts. He has more recently been a member of senior management for four emerging biopharmaceutical companies including ProCyte Corp., BioFrontiers, Inc., AVI BioPharma, and Women’s Capital Corp., where he successfully developed and launched Plan B, a significant product for women’s health care. Gordon was also the first Executive Director of PATH, an influential non-profit organization. He earned his B.S. at Cornell University and his M.S. and Ph.D. at Iowa State University.
Stephan Karr, PhD, Director, Manufacturing & Quality Assurance
Steve spent 11 years as Director of Quality Assurance for Aphton Corporation, directing quality programs and managing contract manufacturers. Aphton was a clinical biopharmaceutical company developing targeted immunotherapies for cancer. Prior to that, he served in laboratory, research and project management positions for Aphton. Steve has a B.A. from California State University, an M.S. from the University of North Carolina and a Ph.D. in Entomology from the University of California at Davis.
|© 2012 CG Therapeutics, Inc.|